The role of N6-methyladenosine modified RNA in Alzheimer's disease12/15/2022 - 11/30/2027 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDNIH/National Institute on Aging5R01AG080810-02
Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology07/01/2021 - 06/30/2026 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDNIH/National Institute on Aging5U01AG072577-04
Nanobodies targeting stress granule components09/01/2023 - 08/31/2025 (Subcontract PI)
University of Connecticut NIH NIA1R21AG083761-01
Genetic Modifiers of Protein Interaction Networks in Tauopathy08/01/2019 - 03/31/2025 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDNIH/National Institute on Aging5R01AG064932-05
TDP-43 aggregation for the treatment of ALS09/15/2015 - 09/14/2024 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDAquinnah Pharmaceuticals, Inc. NIH NINDS1R43NS095481-01
Exploring the pathophysiology of AD and ADRDs with 3D Asteroid models09/15/2021 - 08/31/2024 (PI)
NIH/National Institute on Aging1R56AG074591-01
Systems-level functional proteomics analysis assemblies in Alzheimer's disease and mouse models of tauopathy02/15/2019 - 06/30/2024 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDNIH/National Institute on Aging1RF1AG061706-01
Development of synthetic gene feedback circuits to prevent tau aggregation02/01/2020 - 01/31/2024 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDBright Focus Foundation
Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteins06/01/2018 - 08/31/2023 (PI)
NIH/National Institute on Aging3RF1AG056318-01A1S1
Regulation of brain neuroprotection and inflammation by TIA108/15/2018 - 05/31/2021 (PI)
NIH/National Institute on Aging5R21AG059925-02
Showing 10 of 39 results.
Show All Results
RNA binding proteins as novel targets in Alzheimer's disease09/15/2015 - 04/30/2021 (PI)
NIH/National Institute on Aging5R01AG050471-05
Dysfunction of mRNA metabolism in tauopathy03/01/2018 - 12/31/2019 (Key Person / Mentor)
NIH/National Institute of Neurological Disorders & Stroke5F31NS106751-02
The Role of Acetylation in regulating pathophysiology of tau09/01/2014 - 08/31/2019 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDMayo Clinic NIH NINDS5R01NS089544-05
Targeting Stress Granule Biology in Alzheimer's Disease07/01/2015 - 06/30/2019 (PI)
Bright Focus Foundation
Transformative science driving new treatments for neurodegenerative diseases02/07/2018 - 02/06/2019 (PI)
Pfizer, Inc.
INHIBITiON OF TAU PATHOLOGY IN HUMAN NEURONS07/15/2017 - 07/14/2018 (PI)
Cure Alzheimer's Fund
Targeting RNA Metabolism and the Stress Granule Pathway to Inhibit Tau Aggregation12/31/2015 - 06/30/2018 (PI)
The Edward N. & Della L. Thome Memorial Foundation
It Takes TIA to Tangle: The Role of RNA Binding Proteins in AD01/01/2014 - 06/30/2017 (PI)
Alzheimer's Association
Regulation of RNA translation by MAPT in Alzheimer's disease09/01/2015 - 02/28/2017 (PI)
Cure Alzheimer's Fund
Stress Granules and the Biology of TDP-4301/01/2016 - 12/31/2016 (Multi-PI)
PI:
Benjamin Wolozin, MD, PhDNIH/National Institute of Environmental Health Sciences4R01ES020395-05
Target Identification for TDP-43 Inclusion Inhibitors03/01/2014 - 03/01/2016 (PI)
Massachusetts Life Sciences Center
Stress Granules and the Biology of TDP-4303/01/2012 - 12/31/2015 (PI)
NIH/National Institute of Environmental Health Sciences5R01ES020395-04
Regulation of tau and stress granule interactions by phosphorylation06/01/2014 - 05/31/2015 (PI)
Cure Alzheimer's Fund
Mechanisms and Therapy for Tauopathy Based on RNA Binding Proteins07/01/2013 - 07/31/2014 (PI)
Progressive Supranuclear Palsy Foundation
RNA Binding Proteins in Alzheimer's Disease07/01/2012 - 06/30/2014 (PI)
American Health Assistance Foundation
LRRK2 and Neurodegeneration02/01/2009 - 01/31/2014 (PI)
NIH/National Institute of Neurological Disorders & Stroke5R01NS060872-05
Identification of Compounds that Inhibit Aggregation and Toxicity of TDP-4309/30/2011 - 06/30/2013 (PI)
NIH/National Institute of Neurological Disorders & Stroke5R21NS073679-02
The Role of Stress Granules in the Pathophysiology of TDP-4304/01/2010 - 03/31/2013 (PI)
NIH/National Institute of Neurological Disorders & Stroke5R21NS066108-02
New Small Molecule Inhibiting Agents of Alpha-Synuclein and Lewy Body Formation as Disease-Modifying Treatments for Parkinson’s Disease (LEAPS)01/01/2006 - 12/31/2009 (PI)
ProteoTech Inc. Michael J. Fox Fdn
Developing Inhibitors of TDP-43 Pathology11/01/2008 - 06/30/2009 (PI)
Brigham & Women's Hospital Harvard Med School
Assessing the Potential Receptors for Angiotensin Blockers in Prevention and Treatment of Dementia07/01/2008 - 06/30/2009 (PI)
Retirement Research Foundation
Neurotrophins and Cocaine-Induced Neuronal Plasticity09/17/2004 - 09/16/2008 (Dept Sponsor)
NIH/National Institute on Drug Abuse5 F31 DA17420 03
Mechanisms of Alpha-Synuclein Aggregation and Toxicity07/01/2004 - 06/30/2008 (PI)
Department of Defense/Army
Identification of Compounds that Protect Against Toxins and Genes Implicated in Parkinson’s Disease06/15/2006 - 05/31/2008 (PI)
Michael J. Fox Foundation for Parkinson's Research
Identification of Functional Inhibitors of LRRK209/01/2006 - 08/31/2007 (PI)
Brigham & Women's Hospital NIH NINDS
Mutations in Parkin Cause Autosomal Recessive Juvenile and also Frequently Occur among Patients with Late Onset Parkinson’s Disease (PD)07/01/2005 - 06/30/2007 (PI)
National Parkinson Foundation Inc
Identification of Medicines That Moderate the Incidence of Alzheimer’s Disease01/01/2005 - 12/31/2006 (PI)
Fidelity Foundation
Regulation of APP Processing by Presenilins08/01/2004 - 07/31/2006 (PI)
NIH/National Institute on Aging7 R01 AG17485 04
Ubiquitination/Receptor Signaling-Regulation by Parkin07/01/2004 - 05/31/2006 (PI)
NIH/National Institute of Neurological Disorders & Stroke7 R01 NS41786 05